Trinity Health Grand Rapids is First and Only Hospital in West Michigan Offering Aquablation Therapy for Treatment of Enlarged Prostate
April 3, 2023Categories: Men's Health
New image-guided, heat-free therapy offers long-lasting relief and fewer irreversible complications
GRAND RAPIDS, Mich. (April 4, 2023) – Trinity Health Grand Rapids is the first and only medical facility in West Michigan to offer Aquablation therapy for the treatment of lower urinary tract symptoms (LUTS) in men due to benign prostatic hyperplasia (BPH) or benign enlarged prostate.
Aquablation therapy is an advanced, minimally invasive treatment for BPH that uses imaging, robotics, and a heat-free waterjet to safely remove prostate tissue.
This new, one-of-a-kind treatment is supported by clinical studies that show long-lasting relief and lower rates of irreversible complications, such as erectile dysfunction and incontinence, on prostates of all sizes. It also provides significant symptom relief for men with large prostates.
“As a urologist, the most common condition I see in men is PBH,” said Navneet Mander, MD, Trinity Health Grand Rapids. “Aquablation therapy is a new and exciting option for these patients and the next step to furthering our commitment to men’s health. This solution can provide significant, long-lasting symptom relief with lower risk to their sexual function or continence.
BPH, or an enlarged prostate, is a non-cancerous condition where the prostate has grown to be larger than normal. One in two men ages 51 to 60 have BPH, and the incidence increases every decade of life.
As the prostate grows, it may constrict the urethra, making it difficult to urinate and/or apply pressure on the bladder, causing it to weaken and have difficulty emptying. If left untreated, BPH can cause significant health problems, including irreversible bladder or kidney damage, bladder stones and incontinence.
Because of the potential for adverse effects with current BPH surgical treatments, men may choose to live with symptoms rather than pursue treatment. And while medications to treat BPH do exist, for some, these are not an option.
"Patients may experience negative side effects from BPH medications," said Dr. Mander. "Others may take medications used to treat medical health conditions that may have negative interactions with BPH medications. Aquablation therapy provides a safe and effective alternative to allow these patients to minimize, and potentially discontinue, the need for these BPH medications."
Aquablation therapy uses the AquaBeamâ Robotic System, the first FDA-cleared, surgical robot using automated tissue resection for the treatment of LUTS due to BPH. Aquablation therapy combines real-time, multi-dimensional imaging, automated robotics, and heat-free waterjet ablation for targeted, controlled, and immediate removal of prostate tissue.
Combining both cystoscopic visualization and ultrasound imaging, surgeons can create a personalized treatment plan tailored to each patient’s anatomy. Once the map is complete, the robotically controlled, waterjet ablates the prostate tissue, avoiding critical structures to preserve sexual function and continence.
Numerous clinical studies have shown that Aquablation therapy offers predictable and reproducible outcomes, independent of prostate anatomy, prostate size, or surgeon experience. 2,3,4
“A general screening is necessary to ensure Aquablation therapy is the best fit for the patient. If you are interested, we encourage you to talk with your primary care doctor,” said Dr. Mander.
For more information about Aquablation therapy, visit our website.
About Trinity Health Michigan
Trinity Health Michigan is a leading health care provider and one of the state’s largest employers. With more than 24,000 full-time employees serving 29 counties, Trinity Health Michigan is composed of nine hospitals located in Ann Arbor, Chelsea, Grand Haven, Grand Rapids, Howell, Livonia, Muskegon, Pontiac and Shelby. The health system has 2,314 beds and 5,446 physicians and advanced practice providers. With operating revenues of $4.16 billion, Trinity Health Michigan returns $184 million back to their local communities each year. Together with numerous ambulatory care locations, home health and hospice agencies and 23 senior living communities owned and/or operated by Trinity Health, Trinity Health Michigan provides the full continuum of care for Michigan residents.
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally-invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. PROCEPT designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. PROCEPT has developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 100 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.
Important Safety Information
All surgical treatments have inherent and associated side effects. Individual’s outcomes may depend on a number of factors, including but not limited to patient characteristics, disease characteristics and/or surgeon experience. The most common side effects are mild and transient and may include mild pain or difficulty when urinating, discomfort in the pelvis, blood in the urine, inability to empty the bladder or a frequent and/or urgent need to urinate, and bladder or urinary tract infection. Other risks include ejaculatory dysfunction and a low risk of injury to the urethra or rectum where the devices gain access to the body for treatment. Further, there may be other risks as in other urological surgery, such as anesthesia risk or the risk of infection, including the potential transmission of blood borne pathogens. For more information about potential side effects and risks associated with Aquablation therapy for Benign Prostatic Hyperplasia (BPH) treatment, speak with your urologist or surgeon. Prior to using our products, please review the Instructions for Use, Operator’s Manual or User Manual, as applicable, and any accompanying documentation for a complete listing of indications, contraindications, warnings, precautions and potential adverse events. No claim is made that the AquaBeam® Robotic System will cure any medical condition, or entirely eliminate the diseased entity. Repeated treatment or alternative therapies may sometimes be required.
As with any surgical urologic procedure, potential perioperative risks of the Aquablation procedure include but are not limited to the following, some of which may lead to serious outcomes and may require intervention: Anesthesia risk, Bladder or prostate capsule perforation, Bladder neck contracture, Bleeding or blood in the urine, Bruising, Penile or pelvic pain, Irritative symptoms, which may include dysuria, urgency or frequency, Infection, Transurethral resection (TUR) syndrome, Electric shock/burn, Urethral damage causing false passage or stricture, Rectal incontinence / perforation, Sexual dysfunction, including ejaculatory and erectile dysfunction, Incontinence or overactive bladder, Embolism, Urinary Retention
Rx Only
References:
- Roehrborn, CG, Rosen, RC. Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily. Clinical Interventions in Aging 2008:3(3).
- Gilling et al. Five-year outcomes for Aquablation therapy compared to TURP: a randomized controlled trial in men with LUTS due to BPH Can J Urol 2022; 29(1):10960-10968.
- Zorn KC, Bidair M, Trainer A, Arther A, Kramolowsky E, Desai M, et al. Aquablation therapy in large prostates (80–150 cc) for lower urinary tract symptoms due to benign prostatic hyperplasia: WATER II 3-year trial results. BJUI Compass. 2022;3(2):130–138.
- Bach, T, et al. First Multi-Center All-Comers Study for the Aquablation Procedure. J Clin Med. 2020 Feb; 9(2): 603.